experienced fever or other COVID-like symptoms in the past seven days. Project staff will contact households in which one or more participants reported symptoms to schedule an appointment to collect samples for arbovirus and SARS-CoV-2 molecular testing and to administer a AIS questionnaire about symptoms, exposure and health seeking behaviors. From previous febrile surveillance studies, we expect approximately 40% of household adults will respond to text messages each week and 10% of COPA participants will report acute symptoms and agree to a sample collection visit each year.

Participants with a positive SARS—CoV–2 molecular test will be contacted by phone 2–4 weeks later for a COVID—

19 Case Follow-Up questionnaire on symptoms, health care seeking, potential exposures, and outcomes of SARS–CoV–2 infection. We are expecting that 20% of participants who report symptoms will have a positive COVID–19 result and respond to this follow-up questionnaire.

The central COPA questionnaires (Household, Individual, KAP, Mobility, and Vector Control) will be repeated among approximately 3,800 participants every 12 months, up to a period of five years. The AIS and COVID—19 Follow-Up components will be renewed and modified annually as applicable according to research and funding priorities. This project will allow us to better understand the risk, perceptions,

and burden of arboviral infections and COVID–19 and evaluate a community-based approach for vector control in 38 communities in Ponce, Puerto Rico. The information obtained will inform decision making regarding the location, design, content, and evaluation of future mosquito control interventions implemented in Puerto Rico. Data on incidence and perception of COVID–19 disease will also be used to inform local control programs and fill the current knowledge gaps.

CDC requests OMB approval for an estimated 4,309 annual burden hours. There is no cost to respondents other than the time needed to participate.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Ponce residents from the 38 selected communities 21 years and older or emancipated minor.	Household Representative questionnaire	2,700	1	10/60
Ponce residents from the 38 selected communities 1–50 years old.	Individual questionnaire	3,800	1	20/60
Ponce residents from the 38 selected communities 1–50 years old.	Specimen collection	3,800	1	5/60
Ponce residents from the 38 selected communities 14–50 years old.	Knowledge, Attitudes, and Practices questionnaire.	3,090	1	15/60
Ponce residents from the 38 selected communities 1–50 years old.	Mobility questionnaire	3,800	1	10/60
Ponce residents from the 38 selected communities 21 years and older.	Vector Control questionnaire	2,500	1	10/60
Ponce residents from the 38 selected communities 21 years and older.	AIS text message	1,000	52	0.5/60
Ponce residents from the 38 selected communities with inclusion criteria.	AIS questionnaire	380	1	8/60
Ponce residents from the 38 selected communities with inclusion criteria that tested positive for SAR-CoV-2.	COVID-19 Case Follow-Up questionnaire	75	1	6/60

Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2022–07519 Filed 4–7–22; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Cooperative Agreement To Fund Ministerio de Salud de la República de Panamá (MINSA)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the cancellation of an award of approximately \$10,000,000 for Year 1 of funding to MINSA.

DATES: The notice of award was cancelled on 04/05/2022.

FOR FURTHER INFORMATION CONTACT: Lily de Leon, Center for Global Health, Centers for Disease Control and Prevention, 18 Avenida 11–37, Zona 15, VHIII, 502) 23298426 or (404) 718–2645 USA. Email: izoo@cdc.gov.

SUPPLEMENTARY INFORMATION: On March 9, 2022, CDC announced a single-source award to support MINSA to scale up high-impact HIV prevention, testing and

treatment models in Panama. This award is cancelled in its entirety.

Dated: April 5, 2022.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2022–07542 Filed 4–7–22; 8:45 am]

BILLING CODE 4163-18-P